Loading...
•
Sep 30, 2022
Leap Therapeutics Q3 2022 Earnings Report
Leap Therapeutics reported financial results with a net loss for the third quarter 2022, and progress across the DKN-01 program.
Key Takeaways
Leap Therapeutics reported a net loss of $15.1 million for the third quarter of 2022. The company is focused on advancing its DKN-01 program and has initiated Part C of the DisTinGuish gastric cancer study and the DeFianCe colorectal cancer trial.
Net Loss was $15.1 million for the third quarter 2022.
Research and development expenses were $12.1 million for the three months ended September 30, 2022.
General and administrative expenses were $3.2 million for the three months ended September 30, 2022.
Cash and cash equivalents totaled $78.3 million at September 30, 2022.
Forward Guidance
This press release contains forward-looking statements regarding Leap's expectations with respect to the development and advancement of DKN-01, potential for future payments from BeiGene, financial runway, and other future expectations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...